Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.55 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | GGH | Q92820 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257519 | 0.98 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGGHBMP1 | |
| SCHEMBL22315436 | 0.95 | FOLH1 (0.51) | FOLH1NAALAD2RIMKLAGGHBMP1 | |
| SCHEMBL22315438 | 0.92 | FOLH1 (0.50) | FOLH1NAALAD2RIMKLAGGHFNTA | |
| SCHEMBL22307937 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAGGHBMP1 | |
| SCHEMBL7263008 | 0.90 | FOLH1 (0.47) | FOLH1NAALAD2RIMKLAGGHBMP1 | |
| SCHEMBL27104138 | 0.89 | BMP1 (0.56) | BMP1 | |
| SCHEMBL22315883 | 0.89 | BMP1 (0.42) | FOLH1NAALAD2RIMKLAGGHBMP1 | |
| SCHEMBL22872323 | 0.87 | FOLH1 (0.52) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL1248320 | 0.86 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL9696087 | 0.86 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | FOLH1 4072/4885NAALAD2 984/4885RIMKLA 1754/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | FOLH1 4072/4885NAALAD2 984/4885RIMKLA 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.